Novartis

- WO2009158431 Compounds and compositions as kinase inhibitors

- WO2010026122 Heterocyclic PIM-kinase inhibitors

- WO2010026121 Bicyclic kinase inhibitors

- WO2010006191 4-phenoxymethylpiperidines as modulators of GPR119 activity

- WO2010007027 Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors

- WO2010043584

- WO2010015613

- WO2010002655